Need a mesothelioma lawyer? We will fight for you!
› $4.85 Billion settlement in drug case
As many as 300 product-liability lawsuits may be filed in the Illinois state court against drug maker Baxter International Inc., by people injured by or families who lost loved ones to contaminated batches of the blood thinner heparin. Per a judge’s order last year, attorneys are working to convert an aggregate lawsuit to individual claims against the Deerfield, Illinois-based drug company.
Dusty Martin blamed himself after almost losing his 8-year-old son Michael to a bacterial infection. The boy is a hemophiliac who needs regular injections of medicine to reduce the risk of bleeding to death from a slight cut. Martin uses pre-filled syringes of saline and heparin to flush out the port in his son’s chest before administering his medication. But early last year, shortly after receiving his drugs, Michael began shaking. His temperature shot up to 106 and Martin rushed him to the hospital where he underwent emergency surgery.
A class action lawsuit has been filed against Baxter claiming the drug maker substituted an ingredient in its blood thinner heparin with a cheaper, more dangerous one in order to reap more profits, according to the Madison-St. Clair The Record. Twenty-eight people are named in the lawsuit, most of whom are spouses of individuals who died after receiving injections of the tainted heparin. The lawsuit was filed in St. Clair County Court in Illinois.
The insurance companies for Scientific Protein Laboratories’ parent company, American Capital Ltd., are suing to nullify the policies with the laboratory, according to The Daily Record. The Wisconsin-based company entered a joint venture with Baxter International Inc. to produce heparin in China. Last year, heparin produced at that plant was found to have been contaminated with oversulfated chondroitin sulfate (OSCS), a heparin-mimicking material that can cause life-threatening allergic reactions. The contaminated heparin killed more than 80 people in the U.S. and sickened hundreds more before several batches of the blood thinner were recalled.
Actor Dennis Quaid and his wife Kimberly now have closure in their year-long heparin overdose lawsuit against Cedars-Siani Medical Center, according to OK! and Entertainment Tonight. The entertainment media reported that a Los Angeles judge has signed off on the $750,000 settlement the couple reached with Cedars-Siani last month. According to the settlement, the hospital did not admit wrongdoing in the potentially fatal overdose of heparin that was accidentally administered to the couple’s newborn children Zoe Grace and Thomas Boone Quaid. The settle also allows for the couple to pursue claims for their children in the future. The California Department of Public Heath fined Cedars-Siani $25,000 for the error.
A class action lawsuit has been filed against Baxter Healthcare Corp., claiming the company began substituting ingredients in its anti-coagulant heparin with a dangerous counterfeit to “reap greater profits as a result of utilizing cheap component parts,” according to The Madison St. Clair (Illinois) The Record.
The highly publicized lawsuit between the family of actor Dennis Quaid and Cedars-Sinai Medical Center has been settled, according to The Lowell Sun/Associated Press. Documents show that the Quaids have agreed on a $750,000 settlement with the hospital. The Quaid twins nearly died after they were accidentally given 1,000 times the intended dose of the blood thinner heparin shortly after birth. The settlement allows the couple to pursue claims for their children in the future.
Another lawsuit has been filed against the Wisconsin-based heparin manufacturer, Scientific Protein Laboratories and one of its major distributors, Baxter International Inc., claiming the companies allowed contaminated batches of heparin to reach hospitals and medical facilities, where it led to the death of a 59-year-old hemodialysis patient, according to The News-Enterprise.
The U.S. Food and Drug Administration (FDA) is at odds with congressional investigators over an investigation into the federal agency’s inspection of foreign drug manufacturing facilities.
If Sen. Sherrod Brown (D-OH) has his way, we soon may be able to read the label of prescription medications and learn where they were manufactured. Sen. Brown recently introduced the Transparency in Drug Labeling Act (S. 3633), arguing that Americans have the right to know where their medications are produced, according to Pharmaceutical Technology.
![[ Beasley Allen Law Firm Logo ]](http://www.heparin-legal.com/wp-content/themes/system-unity/images/logo.png){kind=logo}